User menu

Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?

Bibliographic reference Tombal, Bertrand ; Alcaraz, Antonio ; James, Nicholas ; Valdagni, Riccardo ; Irani, Jacques. Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?. In: BJU International, Vol. 113, no. 2, p. 189-199 (2014)
Permanent URL http://hdl.handle.net/2078.1/144379
  1. Epstein M. M., Edgren G., Rider J. R., Mucci L. A., Adami H.-O., Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer, 10.1093/jnci/djs299
  2. D'Amico Anthony V., Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, 10.1001/jama.280.11.969
  3. Bill-Axelson A., Holmberg L., Filen F., Ruutu M., Garmo H., Busch C., Nordling S., Haggman M., Andersson S.-O., Bratell S., Spangberg A., Palmgren J., Adami H.-O., Johansson J.-E., , Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial, 10.1093/jnci/djn255
  4. Wilt Timothy J., Brawer Michael K., Jones Karen M., Barry Michael J., Aronson William J., Fox Steven, Gingrich Jeffrey R., Wei John T., Gilhooly Patricia, Grob B. Mayer, Nsouli Imad, Iyer Padmini, Cartagena Ruben, Snider Glenn, Roehrborn Claus, Sharifi Roohollah, Blank William, Pandya Parikshit, Andriole Gerald L., Culkin Daniel, Wheeler Thomas, Radical Prostatectomy versus Observation for Localized Prostate Cancer, 10.1056/nejmoa1113162
  5. Taverna Gianluigi, Benecchi Luigi, Grizzi Fabio, Seveso Mauro, Giusti Guido, Piccinelli Alessandro, Benetti Alessio, Colombo Piergiuseppe, Minuti Francesco, Graziotti Pierpaolo, Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?, 10.1155/2012/645146
  6. Roach Mack, Waldman Fred, Pollack Alan, Predictive models in external beam radiotherapy for clinically localized prostate cancer, 10.1002/cncr.24348
  7. Beauval Jean-Baptiste, Ploussard Guillaume, Soulié Michel, Pfister Christian, Van Agt Simon, Vincendeau Sébastien, Larue Sébastien, Rigaud Jérome, Gaschignard Nicolas, Rouprêt Morgan, Drouin Sarah, Peyromaure Mickael, Long Jean Alexandre, Iborra Francois, Vallancien Guy, Rozet Francois, Salomon Laurent, Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study, 10.1016/j.urology.2012.04.051
  8. Collette Laurence, Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials, 10.1016/j.eururo.2007.08.041
  9. Peeters Stephanie T.H., Heemsbergen Wilma D., Koper Peter C.M., van Putten Wim L.J., Slot Annerie, Dielwart Michel F.H., Bonfrer Johannes M.G., Incrocci Luca, Lebesque Joos V., Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy, 10.1200/jco.2005.05.2530
  10. Dearnaley DP Jovic G Syndikus I Escalated-dose conformal radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial, on behalf of the RT01 investigators Proceedings of the European Multidisciplinary Cancer Congress, Stockholm, Sweden, 24-27 September 2011 2012
  11. Thompson Ian M., Tangen Catherine M., Paradelo Jorge, Lucia M. Scott, Miller Gary, Troyer Dean, Messing Edward, Forman Jeffrey, Chin Joseph, Swanson Gregory, Canby-Hagino Edith, Crawford E. David, Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial, 10.1016/j.juro.2008.11.032
  12. Bolla Michel, van Poppel Hein, Collette Laurence, van Cangh Paul, Vekemans Kris, Da Pozzo Luigi, de Reijke Theo M, Verbaeys Antony, Bosset Jean-François, van Velthoven Roland, Maréchal Jean-Marie, Scalliet Pierre, Haustermans Karin, Piérart Marianne, Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911), 10.1016/s0140-6736(05)67101-2
  13. Wiegel Thomas, Bottke Dirk, Steiner Ursula, Siegmann Alessandra, Golz Reinhard, Störkel Stephan, Willich Norman, Semjonow Axel, Souchon Rainer, Stöckle Michael, Rübe Christian, Weißbach Lothar, Althaus Peter, Rebmann Udo, Kälble Tilman, Feldmann Horst Jürgen, Wirth Manfred, Hinke Axel, Hinkelbein Wolfgang, Miller Kurt, Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95, 10.1200/jco.2008.18.9563
  14. Bastian Patrick J., Boorjian Stephen A., Bossi Alberto, Briganti Alberto, Heidenreich Axel, Freedland Stephen J., Montorsi Francesco, Roach Mack, Schröder Fritz, van Poppel Hein, Stief Christian G., Stephenson Andrew J., Zelefsky Michael J., High-Risk Prostate Cancer: From Definition to Contemporary Management, 10.1016/j.eururo.2012.02.031
  15. Rosenthal Seth A., Sandler Howard M., Treatment strategies for high-risk locally advanced prostate cancer, 10.1038/nrurol.2009.237
  16. Horwich A., Parker C., Bangma C., Kataja V., , Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 10.1093/annonc/mdq174
  17. Heidenreich, Guidelines on Prostate Cancer (2013)
  18. Spahn Martin, Joniau Steven, Gontero Paolo, Fieuws Steffen, Marchioro Giansilvio, Tombal Bertrand, Kneitz Burkhard, Hsu Chao-Yu, Van Der Eeckt Katie, Bader Pia, Frohneberg Detlef, Tizzani Alessandro, Van Poppel Hein, Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients, 10.1016/j.eururo.2010.03.001
  19. Briganti Alberto, Joniau Steven, Gontero Paolo, Abdollah Firas, Passoni Niccolò M., Tombal Bertrand, Marchioro Giansilvio, Kneitz Burkhard, Walz Jochen, Frohneberg Detlef, Bangma Chris H., Graefen Markus, Tizzani Alessandro, Frea Bruno, Karnes R. Jeffrey, Montorsi Francesco, Van Poppel Hein, Spahn Martin, Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer, 10.1016/j.eururo.2011.11.043
  20. Hsu Chao-Yu, Joniau Steven, Oyen Raymond, Roskams Tania, Van Poppel Hein, Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience, 10.1016/j.eururo.2006.05.024
  21. Huang Jiayi, Vicini Frank A., Williams Scott G., Ye Hong, McGrath Samuel, Ghilezan Mihai, Krauss Daniel, Martinez Alvaro A., Kestin Larry L., Percentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?, 10.1016/j.ijrobp.2011.09.043
  22. Mohler, J Natl Compr Canc Netw, 8, 162 (2010)
  23. National Institute for Health and Clinical Excellence, Prostate Cancer: Diagnosis and Treatment (2008)
  24. Heidenreich Axel, Bellmunt Joaquim, Bolla Michel, Joniau Steven, Mason Malcolm, Matveev Vsevolod, Mottet Nicolas, Schmid Hans-Peter, van der Kwast Theo, Wiegel Thomas, Zattoni Filliberto, EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease, 10.1016/j.eururo.2010.10.039
  25. Rosenthal Seth A., Bae Kyoungwha, Pienta Kenneth J., Sobczak Mark L., Asbell Sucha O., Rajan Raghu, Kerlin Kevin J., Michalski Jeff M., Sandler Howard M., Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02, 10.1016/j.ijrobp.2008.05.020
  26. James Nicholas D., Sydes Matthew R., Clarke Noel W., Mason Malcolm D., Dearnaley David P., Anderson John, Popert Richard J., Sanders Karen, Morgan Rachel C., Stansfeld Jim, Dwyer John, Masters John, Parmar Mahesh K.B., Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial, 10.1111/j.1464-410x.2008.08034.x
  27. Bolla Michel, Hannoun-Levi Jean Michel, Ferrero Jean-Marc, Maingon Philippe, Buffet-Miny Joëlle, Bougnoux Agnès, Bauer Jacques, Descotes Jean-Luc, Fourneret Philippe, Jover Florence, Colonna Marc, Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial, 10.1016/j.radonc.2010.08.012
  28. Spahn Martin, Weiss Christel, Bader Pia, Ströbel Philipp, Gerharz Elmar W., Kneitz Burkard, Frohneberg Detlef, Long-Term Outcome of Patients with High-Risk Prostate Cancer following Radical Prostatectomy and Stage-Dependent Adjuvant Androgen Deprivation, 10.1159/000277593
  29. Ploussard Guillaume, Masson-Lecomte Alexandra, Beauval Jean-Baptiste, Ouzzane Adil, Bonniol Romain, Buge François, Fadli Saad, Rouprêt Morgan, Rebillard Xavier, Gaschignard Nicolas, Pfister Christian, Villers Arnauld, Soulié Michel, Salomon Laurent, Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification, 10.1016/j.urology.2011.05.021
  30. Alcaraz Antonio, Burgos Francisco J., Cózar José M., Gómez-Veiga Francisco, Morote Juan, Solsona Eduardo, Unda Miguel, Carballido Joaquín, Prostate cancer in Spain: from guidelines to clinical practice : PROSTATE CANCER IN SPAIN, 10.1111/j.1464-410x.2010.09832.x
  31. Lughezzani Giovanni, Briganti Alberto, Karakiewicz Pierre I., Kattan Michael W., Montorsi Francesco, Shariat Shahrokh F., Vickers Andrew J., Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature, 10.1016/j.eururo.2010.07.034
  32. Stephenson Andrew J., Kattan Michael W., Eastham James A., Bianco Fernando J., Yossepowitch Ofer, Vickers Andrew J., Klein Eric A., Wood David P., Scardino Peter T., Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era, 10.1200/jco.2008.18.2501
  33. Ficarra Vincenzo, Novara Giacomo, Secco Silvia, D'Elia Carolina, Boscolo-Berto Rafael, Gardiman Marina, Cavalleri Stefano, Artibani Walter, Predictors of Positive Surgical Margins After Laparoscopic Robot Assisted Radical Prostatectomy, 10.1016/j.juro.2009.08.037
  34. Chalfin Heather J., Dinizo Michael, Trock Bruce J., Feng Zhaoyong, Partin Alan W., Walsh Patrick C., Humphreys Elizabeth, Han Misop, Impact of surgical margin status on prostate-cancer-specific mortality : PSM STATUS AND PROSTATE-CANCER-SPECIFIC MORTALITY, 10.1111/j.1464-410x.2012.11371.x
  35. COOPERBERG M, PASTA D, ELKIN E, LITWIN M, LATINI D, DUCHANE J, CARROLL P, THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY, 10.1097/01.ju.0000158155.33890.e7
  36. Cooperberg Matthew R., Broering Jeanette M., Carroll Peter R., Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis, 10.1093/jnci/djp122
  37. YOKOMIZO AKIRA, MURAI MASARU, BABA SHIRO, OGAWA OSAMU, TSUKAMOTO TAIJI, NIWAKAWA MASASHI, TOBISU KEN-ICHI, KINUKAWA NAOKO, NAITO SEIJI, Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan, 10.1111/j.1464-410x.2006.06379.x
  38. Briganti Alberto, Larcher Alessandro, Abdollah Firas, Capitanio Umberto, Gallina Andrea, Suardi Nazareno, Bianchi Marco, Sun Maxine, Freschi Massimo, Salonia Andrea, Karakiewicz Pierre I., Rigatti Patrizio, Montorsi Francesco, Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores, 10.1016/j.eururo.2011.10.044
  39. Vance Sean M., Stenmark Matthew H., Blas Kevin, Halverson Schulyer, Hamstra Daniel A., Feng Felix Y., Percentage of Cancer Volume in Biopsy Cores Is Prognostic for Prostate Cancer Death and Overall Survival in Patients Treated With Dose-Escalated External Beam Radiotherapy, 10.1016/j.ijrobp.2011.09.005
  40. Amin Ali, Partin Alan, Epstein Jonathan I., Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy, 10.1016/j.juro.2011.05.075
  41. Hayashi, BJU Int, 101, 175 (2008)
  42. D'Amico Anthony V., Whittington Richard, Bruce Malkowicz S., Schnall Mitch, Tomaszewski John, Schultz Delray, Kao Gary, Vanarsdalen Keith, Wein Alan, A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer, 10.1016/0360-3016(94)90007-8
  43. Dickinson Louise, Ahmed Hashim U., Allen Clare, Barentsz Jelle O., Carey Brendan, Futterer Jurgen J., Heijmink Stijn W., Hoskin Peter J., Kirkham Alex, Padhani Anwar R., Persad Raj, Puech Philippe, Punwani Shonit, Sohaib Aslam S., Tombal Bertrand, Villers Arnauld, van der Meulen Jan, Emberton Mark, Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting, 10.1016/j.eururo.2010.12.009
  44. Barentsz Jelle O., Richenberg Jonathan, Clements Richard, Choyke Peter, Verma Sadhna, Villeirs Geert, Rouviere Olivier, Logager Vibeke, Fütterer Jurgen J., ESUR prostate MR guidelines 2012, 10.1007/s00330-011-2377-y
  45. Yakar Derya, Debats Oscar A., Bomers Joyce G.R., Schouten Martijn G., Vos Pieter C., van Lin Emile, Fütterer Jurgen J., Barentsz Jelle O., Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer, 10.1002/jmri.22790
  46. Hambrock Thomas, Hoeks Caroline, Hulsbergen-van de Kaa Christina, Scheenen Tom, Fütterer Jurgen, Bouwense Stefan, van Oort Inge, Schröder Fritz, Huisman Henkjan, Barentsz Jelle, Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort, 10.1016/j.eururo.2011.08.042
  47. Latchamsetty, Can J Urol, 14, 3429 (2007)
  48. Heidenreich Axel, Consensus Criteria for the Use of Magnetic Resonance Imaging in the Diagnosis and Staging of Prostate Cancer: Not Ready for Routine Use, 10.1016/j.eururo.2011.01.013
  49. Xylinas Evanguelos, Yates David R., Renard-Penna Raphaële, Seringe Elise, Bousquet Jean-Claude, Comperat Eva, Bitker Marc-Olivier, Grenier Philippe, Rouprêt Morgan, Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination, 10.1007/s00345-011-0811-z
  50. Fütterer Jurgen J., Engelbrecht Marc R., Jager Gerrit J., Hartman Robert P., King Bernard F., Hulsbergen-Van de Kaa Christina A., Witjes J. Alfred, Barentsz Jelle O., Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal–pelvic phased-array coils : Local staging accuracy of prostate cancer using endorectal coil MR imaging, 10.1007/s00330-006-0418-8
  51. Fütterer Jurgen J., Heijmink Stijn W. T. P. J., Scheenen Tom W. J., Jager Gerrit J., Hulsbergen–Van de Kaa Christina A., Witjes J. Alfred, Barentsz Jelle O., Prostate Cancer: Local Staging at 3-T Endorectal MR Imaging—Early Experience, 10.1148/radiol.2381041832
  52. Heijmink Stijn W. T. P. J., Fütterer Jurgen J., Hambrock Thomas, Takahashi Satoru, Scheenen Tom W. J., Huisman Henkjan J., Hulsbergen–Van de Kaa Christina A., Knipscheer Ben C., Kiemeney Lambertus A. L. M., Witjes J. Alfred, Barentsz Jelle O., Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T—Comparison of Image Quality, Localization, and Staging Performance, 10.1148/radiol.2441060425
  53. Zhang Jian Qing, Loughlin Kevin R., Zou Kelly H., Haker Steven, Tempany Clare M.C., Role of Endorectal Coil Magnetic Resonance Imaging in Treatment of Patients with Prostate Cancer and in Determining Radical Prostatectomy Surgical Margin Status: Report of a Single Surgeon’s Practice, 10.1016/j.urology.2007.01.094
  54. Roethke Matthias C., Lichy Matthias P., Kniess Michaela, Werner Matthias K., Claussen Claus D., Stenzl Arnulf, Schlemmer Heinz-Peter, Schilling David, Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy, 10.1007/s00345-012-0826-0
  55. Delongchamps Nicolas Barry, Rouanne Mathieu, Flam Thierry, Beuvon Frédéric, Liberatore Mathieu, Zerbib Marc, Cornud François, Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging : INCREASED PROSTATE CANCER DETECTION WITH MULTIPARAMETRIC MRI, 10.1111/j.1464-410x.2010.09808.x
  56. Durand Xavier, Xylinas Evanguelos, Radulescu Camelia, Haus-Cheymol Rachel, Moutereau Stephane, Ploussard Gillaume, Forgues Aurelien, Robert Grégoire, Vacherot Francis, Loric Sylvain, Allory Yves, Ruffion Alain, de la Taille Alexandre, The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy : VALUE OF URINARY PCA3 SCORE IN PREDICTING PATHOLOGICAL FEATURES ON PROSTATECTOMY SPECIMEN, 10.1111/j.1464-410x.2011.10682.x
  57. van Poppel Hein, Haese Alexander, Graefen Markus, de la Taille Alexandre, Irani Jacques, de Reijke Theo, Remzi Mesut, Marberger Michael, The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance : PCA3 AND PROSTATE CANCER SIGNIFICANCE, 10.1111/j.1464-410x.2011.10377.x
  58. Hessels Daphne, van Gils Martijn P.M.Q., van Hooij Onno, Jannink Sander A., Witjes J. Alfred, Verhaegh Gerald W., Schalken Jack A., Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer, 10.1002/pros.21032
  59. van Gils Martijn P.M.Q., Hessels Daphne, Hulsbergen‐van de Kaa Christina A., Witjes J. Alfred, Jansen Cornelius F.J., Mulders Peter F.A., Rittenhouse Harry G., Schalken Jack A., Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results, 10.1002/pros.20781
  60. Koksal Ismail Turker, Dirice Ercument, Yasar Duygu, Sanlioglu Ahter D, Ciftcioglu Akif, Gulkesen Kemal H, Ozes Nidai O, Baykara Mehmet, Luleci Guven, Sanlioglu Salih, The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma, 10.1016/j.urolonc.2004.01.009
  61. Lotan T. L., Gurel B., Sutcliffe S., Esopi D., Liu W., Xu J., Hicks J. L., Park B. H., Humphreys E., Partin A. W., Han M., Netto G. J., Isaacs W. B., De Marzo A. M., PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients, 10.1158/1078-0432.ccr-11-1244
  62. Cuzick Jack, Swanson Gregory P, Fisher Gabrielle, Brothman Arthur R, Berney Daniel M, Reid Julia E, Mesher David, Speights VO, Stankiewicz Elzbieta, Foster Christopher S, Møller Henrik, Scardino Peter, Warren Jorja D, Park Jimmy, Younus Adib, Flake Darl D, Wagner Susanne, Gutin Alexander, Lanchbury Jerry S, Stone Steven, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study, 10.1016/s1470-2045(10)70295-3
  63. Cuzick J, Berney D M, Fisher G, Mesher D, Møller H, Reid J E, Perry M, Park J, Younus A, Gutin A, Foster C S, Scardino P, Lanchbury J S, Stone S, Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort, 10.1038/bjc.2012.39
  64. Hoogland A Marije, Jenster Guido, van Weerden Wytske M, Trapman Jan, van der Kwast Theo, Roobol Monique J, Schröder Fritz H, Wildhagen Mark F, van Leenders Geert JLH, ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer, 10.1038/modpathol.2011.176
  65. Sreenath, J Carcinog, 11, 37 (2012)
  66. Nam R K, Sugar L, Yang W, Srivastava S, Klotz L H, Yang L-Y, Stanimirovic A, Encioiu E, Neill M, Loblaw D A, Trachtenberg J, Narod S A, Seth A, Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer, 10.1038/sj.bjc.6604054
  67. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur S R, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C, Adami H-O, Mucci L A, Kantoff P W, Andersson S-O, Chinnaiyan A M, Johansson J-E, Rubin M A, TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort, 10.1038/sj.onc.1210237
  68. Shah, Mod Pathol, 22, 193A (2009)
  69. Nanda Akash, Chen Ming-Hui, Renshaw Andrew A., D'Amico Anthony V., Gleason Pattern 5 Prostate Cancer: Further Stratification of Patients With High-Risk Disease and Implications for Future Randomized Trials, 10.1016/j.ijrobp.2008.10.027
  70. Nguyen Paul L., Chen Ming-Hui, Catalona William J., Moul Judd W., Sun Leon, D'Amico Anthony V., Predicting Prostate Cancer Mortality Among Men With Intermediate to High-Risk Disease and Multiple Unfavorable Risk Factors, 10.1016/j.ijrobp.2008.05.009
  71. Loeb Stacy, Schaeffer Edward M., Trock Bruce J., Epstein Jonathan I., Humphreys Elizabeth B., Walsh Patrick C., What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?, 10.1016/j.urology.2009.09.014
  72. Tendulkar Rahul D., Reddy Chandana A., Stephans Kevin L., Ciezki Jay P., Klein Eric A., Mahadevan Arul, Kupelian Patrick A., Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy, 10.1016/j.ijrobp.2011.04.042
  73. Daskivich Timothy J., Chamie Karim, Kwan Lorna, Labo Jessica, Dash Atreya, Greenfield Sheldon, Litwin Mark S., Comorbidity and competing risks for mortality in men with prostate cancer, 10.1002/cncr.26104
  74. Yossepowitch Ofer, Eggener Scott E., Serio Angel M., Carver Brett S., Bianco Fernando J., Scardino Peter T., Eastham James A., Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy, 10.1016/j.eururo.2007.10.008
  75. Muglia Valdair F., Westphalen Antonio C., Wang Zhen J., Kurhanewicz John, Carroll Peter R., Coakley Fergus V., Endorectal MRI of Prostate Cancer: Incremental Prognostic Importance of Gross Locally Advanced Disease, 10.2214/ajr.11.6425
  76. Epstein Jonathan I, Allsbrook William C, Amin Mahul B, Egevad Lars L, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma : , 10.1097/01.pas.0000173646.99337.b1
  77. Pierorazio Phillip M., Ross Ashley E., Lin Brian M., Epstein Jonathan I., Han Misop, Walsh Patrick C., Partin Alan W., Pavlovich Christian P., Schaeffer Edward M., Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy : OUTCOMES FOR HIGH-GLEASON PROSTATE CANCER AT BIOPSY, 10.1111/j.1464-410x.2012.10986.x
  78. Charlson Mary E., Pompei Peter, Ales Kathy L., MacKenzie C.Ronald, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, 10.1016/0021-9681(87)90171-8
  79. Nguyen Paul L., Chen Ming-Hui, Beard Clair J., Suh W. Warren, Choueiri Toni K., Efstathiou Jason A., Hoffman Karen E., Loffredo Marian, Kantoff Philip W., D'Amico Anthony V., Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence, 10.1002/cncr.24818
  80. Kutikov A, Cooperberg M R, Paciorek A T, Uzzo R G, Carroll P R, Boorjian S A, Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram, 10.1038/pcan.2012.21
  81. Daskivich Timothy J., Fan Kang-Hsien, Koyama Tatsuki, Albertsen Peter C., Goodman Michael, Hamilton Ann S., Hoffman Richard M., Stanford Janet L., Stroup Antoinette M., Litwin Mark S., Penson David F., Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer, 10.7326/0003-4819-158-10-201305210-00005
  82. Vickers Andrew, Bennette Caroline, Steineck Gunnar, Adami Hans-Olov, Johansson Jan-Erik, Bill-Axelson Anna, Palmgren Juni, Garmo Hans, Holmberg Lars, Individualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial, 10.1016/j.eururo.2012.04.024
  83. Hamstra Daniel A., Bae Kyounghwa, Pilepich Miljenko V., Hanks Gerald E., Grignon David J., McGowan David G., Roach Mack, Lawton Colleen, Lee R. Jeffrey, Sandler Howard, Older Age Predicts Decreased Metastasis and Prostate Cancer-Specific Death for Men Treated With Radiation Therapy: Meta-Analysis of Radiation Therapy Oncology Group Trials, 10.1016/j.ijrobp.2010.07.2004
  84. Widmark Anders, Klepp Olbjørn, Solberg Arne, Damber Jan-Erik, Angelsen Anders, Fransson Per, Lund Jo-Åsmund, Tasdemir Ilker, Hoyer Morten, Wiklund Fredrik, Fosså Sophie D, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, 10.1016/s0140-6736(08)61815-2
  85. Warde Padraig, Mason Malcolm, Ding Keyue, Kirkbride Peter, Brundage Michael, Cowan Richard, Gospodarowicz Mary, Sanders Karen, Kostashuk Edmund, Swanson Greg, Barber Jim, Hiltz Andrea, Parmar Mahesh KB, Sathya Jinka, Anderson John, Hayter Charles, Hetherington John, Sydes Matthew R, Parulekar Wendy, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, 10.1016/s0140-6736(11)61095-7
  86. Bechis Seth K., Carroll Peter R., Cooperberg Matthew R., Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival, 10.1200/jco.2010.30.2075